Serum autoantibodies against hexokinase 1 manifest secondary to
diabetic macular edema onset

J 2024

Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset

ŠIMČÍKOVÁ, Daniela, Jana IVANČINOVÁ, Miroslav VEITH, Jaroslava DUSOVÁ, Veronika MATUŠKOVÁ et. al.

Basic information

Original name

Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset

Authors

ŠIMČÍKOVÁ, Daniela (203 Czech Republic), Jana IVANČINOVÁ (203 Czech Republic), Miroslav VEITH (203 Czech Republic), Jaroslava DUSOVÁ (203 Czech Republic), Veronika MATUŠKOVÁ (203 Czech Republic, belonging to the institution), Jan NĚMČANSKÝ (203 Czech Republic), Přemysl KUNČICKÝ (203 Czech Republic), Oldřich CHRAPEK (203 Czech Republic, belonging to the institution), Naďa JIRÁSKOVÁ (203 Czech Republic), Jan GOJDA (203 Czech Republic) and Petr HENEBERG (203 Czech Republic)

Edition

Diabetes Research and Clinical Practice, CLARE, ELSEVIER IRELAND LTD, 2024, 0168-8227

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30207 Ophthalmology

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.100 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.diabres.2024.111721

UT WoS

001263613100001

Keywords in English

Autoimmunity; Glycolysis; Disease marker; Disease prediction; Tissue damage; Vitreous fluid

Abstract

V originále

Aims Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset. Materials and methods Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies. Results Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME. Conclusions Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.

Citovat

ŠIMČÍKOVÁ, Daniela, Jana IVANČINOVÁ, Miroslav VEITH, Jaroslava DUSOVÁ, Veronika MATUŠKOVÁ, Jan NĚMČANSKÝ, Přemysl KUNČICKÝ, Oldřich CHRAPEK, Naďa JIRÁSKOVÁ, Jan GOJDA and Petr HENEBERG. Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset. Diabetes Research and Clinical Practice. CLARE: ELSEVIER IRELAND LTD, 2024, vol. 212, June 2024, p. 1-9. ISSN 0168-8227. Available from: https://dx.doi.org/10.1016/j.diabres.2024.111721.

@article{2407820,
   author = {Šimčíková, Daniela and Ivančinová, Jana and Veith, Miroslav and Dusová, Jaroslava and Matušková, Veronika and Němčanský, Jan and Kunčický, Přemysl and Chrapek, Oldřich and Jirásková, Naďa and Gojda, Jan and Heneberg, Petr},
   article_location = {CLARE},
   article_number = {June 2024},
   doi = {http://dx.doi.org/10.1016/j.diabres.2024.111721},
   keywords = {Autoimmunity; Glycolysis; Disease marker; Disease prediction; Tissue damage; Vitreous fluid},
   language = {eng},
   issn = {0168-8227},
   journal = {Diabetes Research and Clinical Practice},
   title = {Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset},
   url = {https://www.sciencedirect.com/science/article/pii/S0168822724006314?via%3Dihub},
   volume = {212},
   year = {2024}
}

TY  - JOUR
ID  - 2407820
AU  - Šimčíková, Daniela - Ivančinová, Jana - Veith, Miroslav - Dusová, Jaroslava - Matušková, Veronika - Němčanský, Jan - Kunčický, Přemysl - Chrapek, Oldřich - Jirásková, Naďa - Gojda, Jan - Heneberg, Petr
PY  - 2024
TI  - Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset
JF  - Diabetes Research and Clinical Practice
VL  - 212
IS  - June 2024
SP  - 1-9
EP  - 1-9
PB  - ELSEVIER IRELAND LTD
SN  - 01688227
KW  - Autoimmunity
KW  - Glycolysis
KW  - Disease marker
KW  - Disease prediction
KW  - Tissue damage
KW  - Vitreous fluid
UR  - https://www.sciencedirect.com/science/article/pii/S0168822724006314?via%3Dihub
N2  - Aims Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset. Materials and methods Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies. Results Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME. Conclusions Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.
ER  -

ŠIMČÍKOVÁ, Daniela, Jana IVANČINOVÁ, Miroslav VEITH, Jaroslava DUSOVÁ, Veronika MATUŠKOVÁ, Jan NĚMČANSKÝ, Přemysl KUNČICKÝ, Oldřich CHRAPEK, Naďa JIRÁSKOVÁ, Jan GOJDA and Petr HENEBERG. Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset. \textit{Diabetes Research and Clinical Practice}. CLARE: ELSEVIER IRELAND LTD, 2024, vol.~212, June 2024, p.~1-9. ISSN~0168-8227. Available from: https://dx.doi.org/10.1016/j.diabres.2024.111721.

Detailed Information on Publication Record